Biotech Values

[DewDiligence]

>After all, the FDA could have rejected [Tyzeka]<

NVS is IDIX’s partner and they don’t screw up very often. Moreover, Telbivudine/Sebivo/Tyzeka had already been approved in Switzerland using essentially the same data package that was submitted to the FDA. So this was a pretty low-risk NDA.

The question now is whether NVS and IDIX can expand the HBV market and capture substantial share from the incumbents. I’m betting that they can.